Clinical trials: KRAS Gene
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Lung Cancer, EGFR Gene Mutation
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
In this study, patients who are taking oral tyrosine kinase inhibitor (TKI) therapy for lung cancer will be asked to participate in a remote monitoring system for up to 24 weeks.
- Conditions
- Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation
- Trial name
- Lung001 (NCT05370469)
- Testing
- Sensus Smartwatch Application, RX Cap, Fitbit Sense
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Virginia
Colorectal Neoplasms
Evaluation of Some Risk Factors Associated With Colorectal Cancer
1. Evaluation of some risk factors (e.g. smoking, heavy metal exposure, and organophosphorus exposure) on CRC. 2. Estimation of KRAS and BRAF genes mutations associated with CRC. 3.
- Trial name
- NCT05170360
- Testing
- Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:
- Volunteers
- 100 people
- Sponsor
- Assiut University
Tumor, Solid
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
- Trial name
- NCT06484556
- Testing
- NW-301V, NW-301D
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Tao Zhang
Lung Neoplasms, KRAS Gene Mutation
Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients
The assessment of the type and frequency of EGFR and KRAS mutations in lung cancer patients, as well as clinical-prognostic correlation, are crucial in the era of targeted therapies.
- Conditions
- Lung Neoplasms, KRAS Gene Mutation, EGFR Gene Mutation
- Trial name
- NCT03171636
- Where
- Brazil
- Volunteers
- 130 people
- Sponsor
- Hospital Erasto Gaertner
Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer…
- Conditions
- Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT01700582
- Where
- 133 sites in France
- Volunteers
- 17,664 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Colorectal Cancer, Metastatic Colorectal Cancer
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for…
- Trial name
- NCT05593328
- Testing
- Onvansertib, FOLFIRI, Bevacizumab
- Where
- 27 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cardiff Oncology
Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
This study will evaluate efficacy and safety of hydroxychloroquine combined with methotrexate, capecitabine and bevacizumab versus regorafenib in participants with refractory metastatic colorectal cancer with mutations in KRAS or…
- Trial name
- x-МАР (NCT06949982)
- Testing
- experimental group x-MAP, Regorafenib (BAY 73-4506)
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Sergey Orlov, MD
Metastatic Solid Cancers, Colorectal Cancer
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses.
- Conditions
- Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT06253520
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Cancer Institute (NCI)
RAS Mutation, Ras (Kras or Nras) Gene Mutation
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the…
- Conditions
- RAS Mutation, Ras (Kras or Nras) Gene Mutation, Colorectal Cancer Recurrent, Pancreas Cancer
- Trial name
- NТО-RAS (NCT06229340)
- Testing
- Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab
- Where
- Russia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back.
- Conditions
- KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02642042
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Trametinib
- Where
- 596 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)